Corcept Therapeutics | CORT - Gross Profit On Sales


Corcept Therapeutics reported $162.02M in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 243.27M 14.49M Mar/2026
Alaunos Therapeutics USD -1.13M 1.11M Sep/2024
ANI Pharmaceuticals USD 124.18M 12.39M Dec/2025
Ardelyx USD 114.37M 8.02M Dec/2025
Assertio Holdings USD 22.24M 970K Jun/2024
Aurora Cannabis CAD 46.62M 14.33M Dec/2025
BioMarin Pharmaceutical USD 571.21M 141.8M Mar/2026
Bristol-Myers Squibb USD 8.41B 381M Dec/2025
Canopy Growth CAD 21.47M 434K Dec/2025
Corcept Therapeutics USD 162.02M 37.56M Mar/2026
Eli Lilly USD 15.92B 1.33B Dec/2025
Esperion Therapeutics USD 140.59M 94.57M Dec/2025
J&J USD 17.24B 642M Mar/2026
Knight Therapeutics CAD 64.72M 8.91M Dec/2025
Lexicon Pharmaceuticals USD 5.29M 8.88M Dec/2025
Merck USD 10.85B 2.57B Dec/2025
Nektar Therapeutics USD 21.81M 8.06M Dec/2025
Novartis USD 10.07B 184M Mar/2026
Novartis USD 10.82B 694M Sep/2025
Omeros USD -33.16M 18.52M Jun/2024
Pacira USD 126.64M 15.61M Mar/2026
Pfizer USD 11.04B 1.24B Mar/2026
Supernus Pharmaceuticals USD 129.36M 34.68M Mar/2026
TG Therapeutics USD 171.41M 16.98M Mar/2026